MOODY’S-ESG-SOLUTIONS
28.10.2021 16:04:07 CEST | Business Wire | Press release
Moody’s ESG Solutions announced today that the Private Infrastructure Development Group (PIDG) has selected Moody’s Climate on Demand scoring tool to assess climate risk exposure in its investment projects.
PIDG mobilizes private investment in sustainable and inclusive infrastructure in sub-Saharan Africa and south and south-east Asia. It will use Moody’s data to screen potential new investments for exposure to climate hazards based on their precise location, and to assess the physical climate risk exposure of assets in its existing portfolio. PIDG’s investment teams and project sponsors will also leverage the data to inform due diligence and climate risk management and mitigation measures.
“We need to ensure that new infrastructure is resilient to the changing climate, especially in the most vulnerable countries,” said Marco Serena, Head of Sustainable Development Impact at PIDG. “Using Moody’s data, we look forward to working with project sponsors and investee companies to understand more about the hazards that investments may be exposed to during their lifetime, and to support increased resilience to the impacts of climate change – not just on the assets themselves but also on the communities that use the infrastructure.”
Moody’s Climate on Demand tool provides a forward-looking view on assets’ exposure to physical climate risks including floods, heat stress, hurricanes and typhoons, sea level rise, water stress, and wildfires. It can score exposure to climate hazards out to the 2030-2040 decade for any location in the world. It allows users to examine specific risk drivers and explore the underlying indicators, capturing various dimensions of risk for each hazard.
“Integrating exposure to physical climate hazards into financing and development is essential to ensure the long-term viability of infrastructure assets, and to help inform targeted resilience measures,” said Emilie Mazzacurati, Global Head of Moody’s Climate Solutions. “We are pleased that PIDG has chosen to use our Climate on Demand tool as part of its critical efforts to drive investment in climate resilience.”
To learn more about Moody’s Climate Solutions, visit: https://esg.moodys.io/climate-solutions .
ABOUT MOODY’S ESG SOLUTIONS
Moody’s ESG Solutions Group is a business unit of Moody’s Corporation serving the growing global demand for ESG and climate insights. The group leverages Moody’s data and expertise across ESG, climate risk, and sustainable finance, and aligns with Moody's Investors Service and Moody's Analytics to deliver a comprehensive, integrated suite of ESG and climate risk solutions including ESG scores, analytics, Sustainability Ratings and Sustainable Finance Reviewer/certifier services. For more information, visit https://esg.moodys.io/solutions#solutions .
ABOUT PRIVATE INFRASTRUCTURE DEVELOPMENT GROUP
The Private Infrastructure Development Group (PIDG) is an innovative infrastructure project developer and investor which mobilises private investment in sustainable and inclusive infrastructure in sub-Saharan Africa and south and south-east Asia. PIDG investments promote socio-economic development within a just transition to net zero emissions, combat poverty and contribute to the Sustainable Development Goals (SDGs). PIDG delivers its ambition in line with its values of opportunity, accountability, safety, integrity and impact. Since 2002, PIDG has supported 171 infrastructure projects to financial close which provided an estimated 217 million people with access to new or improved infrastructure. PIDG is funded by the governments of the United Kingdom, the Netherlands, Switzerland, Australia, Sweden, Germany and the IFC. For more information visit www.pidg.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005777/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
